Brief: Citius Pharmaceuticals, Inc. Announces U.S. Food And Drug Administration Acceptance Of Biologics License Application Of Denileukin Diftitox For The Treatment Of Patients With Persistent Or Recurrent Cutaneous T-Cell Lymphoma
01/12/2022 12:35
Dec 1 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS, INC. ANNOUNCES U.S. FOOD AND DRUG
ADMINISTRATION ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION OF
DENILEUKIN DIFTITOX FOR THE TREATMENT OF PATIENTS WITH
PERSISTENT OR RECURRENT CUTANEOUS T-CELL LYMPHOMA
* CITIUS PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE
ACT
TARGET ACTION DATE IS SEPTEMBER 28, 2023
Source text for Eikon: ID:nPn8nHy4ta
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules